Austin biotech Mol­e­c­u­lar Tem­plates lays off more than 100 staffers as pipeline nar­rows

Mol­e­c­u­lar Tem­plates is rid­ding it­self of a Phase I HER2 as­set and fine-tun­ing its pipeline to fo­cus on three pro­grams and a pre­clin­i­cal Bris­tol My­ers Squibb col­lab­o­ra­tion. With the nar­rowed scope on its so-called en­gi­neered tox­in bod­ies, the Austin, TX biotech is lay­ing off about half of its staff.

That’s a lit­tle more than 100 em­ploy­ees, per an SEC fil­ing. Mol­e­c­u­lar’s lay­offs, ap­proved by its board Wednes­day, add to the dozens of pull­backs in the in­dus­try in the first three months of 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER